RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
anlotinib Sensitive: C3 – Early Trials
BMC Med - 2 weeks (NewC3)
|
anlotinib Sensitive: C3 – Early Trials
BMC Med - 2 weeks - (New C3)
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
panitumumab Sensitive: A1 - Approval
|
panitumumab Sensitive: A1 - Approval
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
fruquintinib Sensitive: B - Late Trials
|
fruquintinib Sensitive: B - Late Trials
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
bevacizumab Sensitive: B - Late Trials
|
bevacizumab Sensitive: B - Late Trials
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
ramucirumab Sensitive: C2 – Inclusion Criteria
|
ramucirumab Sensitive: C2 – Inclusion Criteria
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria
|
bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
avelumab Sensitive: C3 – Early Trials
|
avelumab Sensitive: C3 – Early Trials
|
RAS wild-type
|
Colon Cancer
|
RAS wild-type
|
Colon Cancer
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|